Myelodysplastic Syndromes

Dao, Kim

doi:10.1016/j.mcna.2016.09.006

Cited by 14 publications

(11 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this cohort, the disease was more frequent in females, with a ratio of 1:2.5 and the mean age at diagnosis was 53.8 years. These findings were not in agreement with those of Bănescu et al (2011) and Dao (2017) who found that male are affected more than females with a male/female ratio of 1.44 to 1 and 1.26 to 1, respectively. Despite data from population-based registries on the incidence and prevalence of MDS, other reports also show a predominance of the disease in males (Gologan, 2010;Neukirchen et al, 2011;Lubeck et al, 2016).…”

Section: Discussioncontrasting

confidence: 90%

Research Article High diversity of chromosomal aberrations in a Brazilian myelodysplastic syndrome cohort

Ribeiro¹,

Pinto²,

Diogo³

et al. 2019

Genet. Mol. Res.

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS), an oncohematological disease, is characterized by distinct levels of peripheral blood cytopenia, cell differentiation dysplasia and various types of chromosomal alterations. The Revised International Prognostic Scoring System uses the GTG-banding karyotype as one of the main components for scoring patient prognosis in MDS. Using GTG-banding karyotyping, we looked for chromosomal alterations in bone marrow samples obtained from a cohort of Brazilian patients in Goiás state, Brazil. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 18 (2): gmr18322 C.L. Ribeiro et al. 2Numerical and/or structural chromosomal alterations were detected in 15 of 29 patients. A total of 23 clones with the chromosomal alterations were obtained, of which 12 were numerical and 11 were structural. Complete trisomies were observed in five clones, complete monosomies in three clones, triploidies in three clones, and one clone contained a marker chromosome. Among the clones with structural alterations, two clones had a partial trisomy in 1q, five clones had partial monosomies, one clone contained an isochromosome, and three clones showed reciprocal translocations. The high diversity of chromosomal alterations is inherent to the strong degree of chromosomal and genomic instability in this myeloid disease. These alterations can be associated with the activation or inhibition of gene expression, leading to the deregulation of critical cell viability functions and hence ineffectiveness of hematopoiesis in MDS. Our study is the first to identify chromosomal alterations associated with this poorly studied disease in central Brazil.

show abstract

Section: Discussioncontrasting

confidence: 90%

Research Article High diversity of chromosomal aberrations in a Brazilian myelodysplastic syndrome cohort

Ribeiro¹,

Pinto²,

Diogo³

et al. 2019

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Myelodysplastic syndrome (MDS) comprises a heterogeneous group of clonal myeloid disorders characterized by debilitating peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers1. MDS is typically considered as a neoplasm because of frequent genetic aberrations, limited patient survival, and progression to acute myeloid leukemia (AML) 2.…”

Section: Introductionmentioning

confidence: 99%

Gender disparity in the survival of patients with primary myelodysplastic syndrome

Wang¹,

Ni²,

Wu³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Several prognostic scoring systems have been developed to assess prognosis in myelodysplastic syndrome (MDS). However, currently there are no systems that list gender as a prognostic factor. We queried a National Cancer Institute database to investigate the prognostic influence of gender on the survival of patients with MDS. We first identified 34,681 qualified patients diagnosed with MDS from 2001-2014 in the Surveillance, Epidemiology, and End Results (SEER) database, and then analyzed the characteristics of these patients using chi-squared tests. The Kaplan-Meier method and the multivariate Cox regression model were used to examine whether gender disparity in the survival of patients with MDS existed. We found that male patients had higher incidence rate of MDS (55.3% vs 44.7%, P<0.001) and a significant survival disadvantage (27.6% vs 33.6%, P<0.001) compared to female patients. Moreover, the less favorable survival rate of male MDS patients was associated with the age at diagnosis, race, marital status at diagnosis and the histological subtypes including refractory anemia (RA), refractory cytopenia with multilineage dysplasia (RCMD), myelodysplastic associated with isolated del 5q (MDS 5q-), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and not otherwise specified (NOS). In conclusion, gender can be considered as an independent prognostic factor for the overall survival of patients with MDS.

show abstract

“…Advances in massively parallel sequencing technology have enabled the genetic characterization of MDS over the last five years, to the point where the focus has now shifted to translating these findings to improve patient outcomes. Further, in the last 10 years, the Food and Drug Administration has approved the use of three MDS therapeutics, in addition to several groups genetically characterizing MDS to a greater extent than before [ 8 ]. The genetic data will assist in diagnosing MDS with equivocal pathologic data and will eventually improve the use of novel and existing drugs, whether they be monotherapies or combination therapies.…”

Section: Introductionmentioning

confidence: 99%

“…The genetic data will assist in diagnosing MDS with equivocal pathologic data and will eventually improve the use of novel and existing drugs, whether they be monotherapies or combination therapies. Moreover, these data will enhance the treatment of MDS patients post-allogeneic bone marrow transplant (BMT) [ 8 ].…”

Section: Introductionmentioning

confidence: 99%